Tags

Type your tag names separated by a space and hit enter

[Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease].
No To Shinkei. 1998 Feb; 50(2):157-63.NT

Abstract

Effects of L-threo-Dops (Dops) administration on orthostatic hypotention were evaluated with changes in blood pressure by postural change (lying to standing position) and subjective symptoms in 15 patients of Parkinson's disease having symptoms of orthostatic hypotention. Orthostatic syncope had improved significantly (p < 0.01) after 2 and 4 weeks of administration with maintenance dose of 460 mg/day of Dops in average. In the standing-up (Schellong) test, decrease in blood pressure levels by a postural change, both with systolic and diastolic blood pressure, was significantly smaller at 3, 5 and 10 minutes after standing after 4 weeks of drug administration. Decrease in the blood pressure level immediately after standing-up improved by 10.2 +/- 4.0 for systolic and 6.5 +/- 1.8 for diastolic (mmHg, mean +/- SE) (p < 0.01). The group that showed improvement in orthostatic syncope had a significant improvement in decline in blood pressure by standing after administration of Dops, while the group without any change in severity of syncope did not show significant improvement in orthostatic hypotention.

Authors+Show Affiliations

Department of Medicine (Neurology), Shinshu University School of Medicine, Matsumoto, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

jpn

PubMed ID

9513205

Citation

Yanagisawa, N, et al. "[Effects of L-threo-Dops On Orthostatic Hypotension in Parkinson's Disease]." No to Shinkei = Brain and Nerve, vol. 50, no. 2, 1998, pp. 157-63.
Yanagisawa N, Ikeda S, Hashimoto T, et al. [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease]. No To Shinkei. 1998;50(2):157-63.
Yanagisawa, N., Ikeda, S., Hashimoto, T., Hanyu, N., Nakagawa, S., Fujimori, N., & Ushiyama, M. (1998). [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease]. No to Shinkei = Brain and Nerve, 50(2), 157-63.
Yanagisawa N, et al. [Effects of L-threo-Dops On Orthostatic Hypotension in Parkinson's Disease]. No To Shinkei. 1998;50(2):157-63. PubMed PMID: 9513205.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease]. AU - Yanagisawa,N, AU - Ikeda,S, AU - Hashimoto,T, AU - Hanyu,N, AU - Nakagawa,S, AU - Fujimori,N, AU - Ushiyama,M, PY - 1998/3/26/pubmed PY - 1998/3/26/medline PY - 1998/3/26/entrez SP - 157 EP - 63 JF - No to shinkei = Brain and nerve JO - No To Shinkei VL - 50 IS - 2 N2 - Effects of L-threo-Dops (Dops) administration on orthostatic hypotention were evaluated with changes in blood pressure by postural change (lying to standing position) and subjective symptoms in 15 patients of Parkinson's disease having symptoms of orthostatic hypotention. Orthostatic syncope had improved significantly (p < 0.01) after 2 and 4 weeks of administration with maintenance dose of 460 mg/day of Dops in average. In the standing-up (Schellong) test, decrease in blood pressure levels by a postural change, both with systolic and diastolic blood pressure, was significantly smaller at 3, 5 and 10 minutes after standing after 4 weeks of drug administration. Decrease in the blood pressure level immediately after standing-up improved by 10.2 +/- 4.0 for systolic and 6.5 +/- 1.8 for diastolic (mmHg, mean +/- SE) (p < 0.01). The group that showed improvement in orthostatic syncope had a significant improvement in decline in blood pressure by standing after administration of Dops, while the group without any change in severity of syncope did not show significant improvement in orthostatic hypotention. SN - 0006-8969 UR - https://www.unboundmedicine.com/medline/citation/9513205/[Effects_of_L_threo_Dops_on_orthostatic_hypotension_in_Parkinson's_disease]_ L2 - https://ClinicalTrials.gov/search/term=9513205 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -